Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer

Objective: To investigate the correlation of metabolic syndrome (MS) and its components with the clinicopathological features in patients with pancreatic cancer and their prognostic impact, so as to provide a theoretical reference for the comprehensive prevention and treatment of pancreatic cancer.Methods: A retrospective analysis was conducted on the case data of 184 patients with pancreatic cancer who received treatment at the First Affiliated Hospital of Guangxi Medical University from January 2017 to December 2021.Based on the diagnostic criteria for metabolic syndrome, the 144 cases were divided into non-MS group (n=104) and MS group (n=40).Cox regression model was used to analyze prognostic factors in 49 patients without anticancer treatment, while Kaplan-Meier method was employed to examine the relationship between MS and its components with prognosis.Results: Compared with the non-MS group, the MS group exhibited advanced TNM stage and a higher incidence rate of distant metastasis (P< 0.05).Low level of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia were independent risk factors for TNM staging of pancreatic cancer(P< 0.05).The median survival time for the 49 patients without anticancer therapy was determined as 2.5 months.Survival analysis showed that advanced TNM stage and hyperglycemia were independent risk factors for survival time (P< 0.05), and the median survival time of stage Ⅳpatients was 2.2 months.Hyperglycemia was an independent risk factor for the prognosis of stage Ⅳpatients, and overweight was a protective factor(both P< 0.05).There was no statistical significance in survival time between MS patients and non-MS patients(P> 0.05), and there was no statistical significance in median survival time between patients with or without hypertension, high triglyceride (TG) and low HDL-C(all P> 0.05).Conclusion: MS is related to clinical stage and incidence of distant metastasis of pancreatic cancer patients, but it has not been proved to be an influencing factor for the survival of patients.Hyperglycemia and overweight are risk factors and protective factors for the prognosis of patients.